This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
CovalX AG was originally a Zürich, Switzerland-based company that developed High Mass MALDI detection systems, a mass spectrometric platform for characterizing therapeutic proteins.
 | |
| Company type | Private |
|---|---|
| Industry | Life Sciences |
| Founded | 2005 |
| Founder | Ryan Wenzel Alexis Nazabal Urs Matter |
| Headquarters | , |
Area served | Worldwide |
| Products | CRO Business |
| Services | MS Analysis |
| Website | https://covalx.com/ |
Origins
editA spin-off of the Swiss Federal Institute of Technology (ETHZ), CovalX was founded by Ryan Wenzel, Alexis Nazabal, and Urs Matter in 2005 as CovalX GmbH and was converted in January 2007 to AG status to allow additional investors into the company.
In 2011, CovalX founded a wholly owned US subsidiary called CovalX Instruments Incorporated located in the Boston area. They began manufacturing and testing the mass spectrometry instruments based on their proprietary technique as well as sales and support for their hardware products.
CovalX developed and patented a technology platform based on mass spectrometry allowing ultra-fast and direct analysis of protein-protein interactions (PPIs) in solution, called High Mass MALDI. The technology has been named on many patents including:
- Abbvie: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.
- Aix Marseille Universite: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.
Since 2009, CovalX began focusing on analytical service measurements through its growing CRO laboratories and physical locations in Switzerland, France and the US. Today the company specializes in characterization services for biotherapeutics using its proprietary mass spectrometry solutions. Combining its unique technology platform in combination with other methods such as Hydrogen–deuterium exchange by mass-spectrometry (HDX-MS) and Cross-linking by mass-spectrometry (XL-MS), the company helps scientists worldwide in biotherapeutic development projects.
Applications:
Notable Citations:
CovalX and its proprietary platform has been cited in many leading publications:
- Xibei Dang, Lars Guelen, David Lutje Hulsik, Grigori Ermakov, Edward J. Hsieh, Joost Kreijtz, Judith Stammen-Vogelzangs, Imke Lodewijks, Astrid Bertens, Arne Bramer, Marco Guadagnoli, Alexis Nazabal, Andrea van Elsas, Thierry Fischmann, Veronica Juan, Amy Beebe, Maribel Beaumont & Hans van Eenennaam (2023) Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies, mAbs, 15:1, DOI: 10.1080/19420862.2023.2285285
- Rennert PD, Dufort FJ, Su L, Sanford T, Birt A, Wu L, Lobb RR, Ambrose C. Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo. Mol Cancer Ther. 2021 Oct;20(10):2071-2081. doi: 10.1158/1535-7163.MCT-20-1030. Epub 2021 Jul 12. PMID: 34253594; PMCID: PMC9398100.
- ACS Bio Med Chem Au 2021, 1, 1, 31–43 Publication Date:September 10, 2021. https://doi.org/10.1021/acsbiomedchemau.1c00021. Stable Gold-Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens Kevin R. Trabbic, Kristopher A. Kleski, and Joseph J. Barchi Jr
https://patents.google.com/patent/US20230183369A1
https://patents.google.com/patent/AU2021270458A1
Awards
editIn April 2006, CovalX received the CTI Start-up Label from the Swiss Confederation's Commission for Technology and Innovation.[2]